NCT00811369View on ClinicalTrials.gov

Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

August 31, 2013

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Fulvestrant + ZACTIMA

ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance

DRUG

Fulvestrant + Placebo

ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.

Trial Locations (13)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

British Columbia Cancer Agency - Vancouver Centre, Vancouver

B3H 1V7

QE II Health Sciences Centre, Halifax

P3E 5J1

Regional Cancer Program of the Hôpital régional de Sudbury Regional Hospital, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre, Hamilton

N2G 1G3

Grand River Regional Cancer Centre, Kitchener

L1G 2B9

RSM Durham Regional Cancer Centre, Oshawa

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

M4N 3M5

Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H2W 1T7

Centre Hospitalier De L'Universite De Montreal - Hotel Dieu, Montreal

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER